OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Vergote on the Need to Develop Novel Therapies in Endometrial Cancer

June 11th 2020

Ignace B. Vergote, MD, PhD, discusses the need to develop novel therapies in endometrial cancer.

Dr. Hope on Using 68Ga-PSMA-11 to Detect Pelvic Nodal Metastasis in Prostate Cancer

June 11th 2020

Thomas Hope, MD, discusses the rationale for using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Dr. Morgan the Evolution of Treatment in Multiple Myeloma

June 11th 2020

Gareth J. Morgan, MD, PhD, discusses the evolution of treatment options in multiple myeloma.

Dr. Matulonis on Final Data From KEYNOTE-100 in Recurrent Ovarian Cancer

June 11th 2020

Ursula A. Matulonis, MD, discusses final data from the phase 2 KEYNOTE-100 trial with pembrolizumab (Keytruda) in advanced recurrent ovarian cancer.

Dr. Salani on Opportunities for Precision Medicine in Cervical Cancer

June 11th 2020

Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.

Dr. Weitzman on Sequencing Challenges in Myeloma Treatment

June 11th 2020

James Weitzman, MD, medical oncologist, Emerson Hospital and Waltham Cancer Center of Massachusetts General Cancer Center, discusses sequencing challenges in multiple myeloma treatment.

Dr. DiNardo on Timing and Impact of Response to Venetoclax Combinations in AML

June 11th 2020

Courtney DiNardo, MD, MSCE, iscusses findings from a pooled analysis examining venetoclax (Venclexta) combination treatment in acute myeloid leukemia.

Dr. Jacobson on the Benefit of Axi-Cel in Relapsed/Refractory Follicular Lymphoma

June 11th 2020

Caron Jacobson, MD, discusses the benefit of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed/refractory follicular lymphoma.

Dr. Saad on the SPARTAN Trial in M0CRPC

June 10th 2020

Fred Saad, MD, FRCS, discusses the randomized phase 3 SPARTAN trial in nonmetastatic castration-resistant prostate cancer.

Dr. Karmali on the Importance of Evaluating Older Patients With MCL in the Rituximab Era

June 10th 2020

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Dr. Karmali on the Importance of Evaluating Older Patients With MCL in the Rituximab Era

June 10th 2020

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Dr. Lee on Early Efficacy Data With Cirmtuzumab/Ibrutinib in MCL

June 10th 2020

Hun Ju Lee, MD, discusses early efficacy data from a phase 1b/2 study of the investigational ROR1 inhibitor cirmtuzumab in combination with ibrutinib in patients with relapsed/refractory mantle cell lymphoma.

Dr. Chaft on Considerations for Restarting Immunotherapy in Lung Cancer

June 10th 2020

Jamie E. Chaft, MD, discusses considerations for restarting immunotherapy in patients with lung cancer.

Dr. Wang on the Impact of KTE-X19 on Outcomes in Higher- Versus Lower-Risk MCL

June 10th 2020

Michael Wang, MD, discusses the safety and effectiveness of the autologous anti-CD19 CAR T-cell therapy KTE-X19 in patients with higher- versus lower-risk mantle cell lymphoma.

Dr. Kelly on Efficacy of Radium-223 Dichloride and Niraparib in Patients With mCRPC

June 10th 2020

William K. Kelly, DO, discusses results from a phase 1b dose-finding study evaluating the combination of radium-223 dichloride (Xofigo) plus niraparib (Zejula) in patients with metastatic castration-resistant prostate cancer.

Dr. Musher on Immunotherapy Versus TKIs in HCC

June 10th 2020

Benjamin Leon Musher, MD, discusses immunotherapy versus TKIs in hepatocellular carcinoma.

Dr. Tolaney on CNS Recurrence in HER2+ Breast Cancer

June 10th 2020

Sara M. Tolaney, MD, MPH, discusses the unmet need with regard to effectively preventing central nervous system recurrence in HER2-positive breast cancer.

Dr. Cortes on Updated PFS Data From KEYNOTE-355 in PD-L1-High TNBC

June 9th 2020

Javier Cortes, MD, PhD, discusses updated progression-free survival data from the phase 3 KEYNOTE-355 study with pembrolizumab plus chemotherapy in previously untreated patients with locally recurrent, inoperable or metastatic triple-negative breast cancer.

Dr. Flinn on the Role of BTK Inhibitors in CLL

June 9th 2020

Ian W. Flinn, MD, PhD, discusses the role of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Flinn on the Role of BTK Inhibitors in CLL

June 9th 2020

Ian W. Flinn, MD, PhD, discusses the role of BTK inhibitors in chronic lymphocytic leukemia.